Mirae Asset Global Investments Co. Ltd. boosted its position in Immunocore Holdings plc (NASDAQ:IMCR – Free Report) by 28.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,152 shares of the company’s stock after buying an additional 3,623 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Immunocore were worth $1,104,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Immunocore by 103.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after purchasing an additional 426 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Immunocore by 32.9% during the 3rd quarter. IFP Advisors Inc now owns 2,397 shares of the company’s stock valued at $124,000 after buying an additional 594 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock worth $181,000 after buying an additional 674 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Immunocore by 1.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company’s stock valued at $5,639,000 after buying an additional 1,513 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in Immunocore by 26.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock valued at $389,000 after acquiring an additional 1,572 shares during the period. 84.50% of the stock is currently owned by institutional investors.
Immunocore Stock Up 0.3 %
Shares of IMCR opened at $55.82 on Tuesday. The firm has a market cap of $2.78 billion, a P/E ratio of -48.12 and a beta of 0.89. Immunocore Holdings plc has a 1 year low of $42.21 and a 1 year high of $76.98. The stock has a 50 day simple moving average of $63.38 and a two-hundred day simple moving average of $60.54. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.80 and a quick ratio of 3.77.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and issued a $87.00 price target (up from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Immunocore in a research report on Wednesday, March 6th. JPMorgan Chase & Co. upped their target price on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Canaccord Genuity Group raised their price target on shares of Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a report on Thursday, February 29th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research report on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $80.55.
Read Our Latest Research Report on Immunocore
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Stories
- Five stocks we like better than Immunocore
- Health Care Stocks Explained: Why You Might Want to Invest
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Merger or Not, Albertson’s Companies is a Good Buy
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Cheap Stocks That Shouldn’t Be So
Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc (NASDAQ:IMCR – Free Report).
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.